Evidence map›Paper›PMID 37020544›Full record

ArticleFrontiers in immunology2023

Abundance of

Anucha Preechanukul, Thatcha Yimthin, Sarunporn Tandhavanant, Tobias Brummaier, Chalita Chomkatekaew, Sukanta Das, Basirudeen Syed Ahamed Kabeer, Mohammed Toufiq, Darawan Rinchai, T Eoin West and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Anucha PreechanukulDepartment of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Thatcha YimthinDepartment of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Sarunporn TandhavanantDepartment of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Tobias BrummaierSwiss Tropical and Public Health Institute, Basel, Switzerland.
Chalita ChomkatekaewMahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Sukanta DasMahidol-Oxford Tropical Medicine Research Unit (MORU), Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Basirudeen Syed Ahamed KabeerSystems Biology and Immunology Department, Sidra Medicine, Doha, Qatar.
Mohammed ToufiqSystems Biology and Immunology Department, Sidra Medicine, Doha, Qatar.
Darawan RinchaiSystems Biology and Immunology Department, Sidra Medicine, Doha, Qatar.
T Eoin WestDepartment of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Damien ChaussabelSystems Biology and Immunology Department, Sidra Medicine, Doha, Qatar.
Narisara ChantratitaDepartment of Microbiology and Immunology, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Mathieu GarandSystems Biology and Immunology Department, Sidra Medicine, Doha, Qatar.
Mahidol Oxford Tropical Medicine Research Unit · THMahidol University · THUniversity of Basel · CHWashington University in St. Louis · US

Funding

Determinants of Outcome and Recurrent Infections in MelioidosisU01AI115520 · NIAID · MAHIDOL UNIVERSITY · PI CHANTRATITA, NARISARA, WEST, TIMOTHY EOIN · 2015 to 2019
$2.0M
NIAID NIH HHS U01 AI115520Wellcome TrustWellcome Trust 220211
6 · The paper itself

Abstract

Sepsis is a complex heterogeneous condition, and the current lack of effective risk and outcome predictors hinders the improvement of its management. Using a reductionist approach leveraging publicly available transcriptomic data, we describe a knowledge gap for the role of ACVR1B (activin A receptor type 1B) in sepsis. ACVR1B, a member of the transforming growth factor-beta (TGF-beta) superfamily, was selected based on the following: 1) induction upon

Indexed as

MelioidosisSepsisActivin Receptors, Type IHumansTransforming Growth Factor betaActivin Receptors, Type IACVR1B protein, humanTransforming Growth Factor betaactivin Ablood transcriptomicsinnate immunitymelioidosissepsis

Identifiers

PMID37020544
PMCPMC10067751
OpenAlexW4327978373

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.